Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Exclusion Criteria

• •1. Patients who are measured the difference of mean blood pressure of one arm under sitting diastolic blood pressure(SiDBP) 10mmHg or SiSBP 20mmHg at screening and baseline visit
• •2. more 170mmHg of mean Sitting systolic blood pressure(SiSBP)or more 110mmHg of mean Sitting diastolic blood pressure(SiDBP) before exercise at baseline(Day 0)
• •3. Patients with secondary hypertension
• •4. Patients with orthostatic hypotension who has sign and symptom
• •5. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c\>9, regimen change of oral hypoglycemic agent, using insulin)
• •6. Patients with severe heart disease, ischemic heart disease within 6 months, peripheral vascular disease, Percutaneous transluminal coronary angiography(PTCA), Coronary artery bypass graft(CABG)
• •7. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia
• •8. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve disease
• •9. Patients with severe cerebrovascular disease
• •10. Patients with known severe or malignancy retinopathy
• •11. Patients with wasting disease, autoimmune disease, connective tissue disease at present and/or previous
• •12. Patients with significant investigations; abnormal renal function (Creatinine more 1.5 times than upper limit of normal), abnormal liver function(AST, ALT more 2 times than upper limit of normal), severe fatty liver disease needed medication
• •13. Patients with surgical and medical disease that is able to be affect to absorption, distribution, metabolism and excretion
• •14. Patients who have a story or evidence of alcohol or drug abuse within 2 years
• •15. Childbearing and breast-feeding women
• •16. Female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods
• •17. Patients with Bronchial Asthma
• •18. Patients expected to live less than 1 year with tumor or chronic disease
• •19. Patients with hepatitis B or C
• •20. Patients with history of allergic reaction to any angiotensin II antagonist
• •21. Patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial
• •22. Subject who are judged unsuitable to participate in this clinical trial by investigator